MergerAug 3, 2026, 06:32 AM
Supernus & Indivior Merge in All-Stock Deal; $2.2B Combined Revenue
AI Summary
Supernus Pharmaceuticals and Indivior Pharmaceuticals announced a definitive agreement to combine in a tax-free all-stock merger of equals. The combined entity, to be named Supernus, Inc., will create a leading diversified CNS biopharmaceutical company with approximately $2.2 billion in combined annual revenues and $888 million in pro forma adjusted EBITDA. The transaction is expected to generate $125 million in annual cost synergies and close in Q4 2026, with Jack Khattar serving as President and CEO.
Key Highlights
- Supernus and Indivior to combine in a tax-free all-stock merger of equals.
- Combined company expected to have approximately $2.2 billion in annual revenues.
- Transaction expected to generate $125 million in annual cost synergies.
- Combined pro forma adjusted EBITDA of $888 million.
- Combined entity named Supernus, Inc.; Jack Khattar to serve as President and CEO.
- Indivior stockholders to own approximately 56.5% of the combined company.
- Indivior stockholders to receive a $1.0 billion special cash dividend.
- Transaction is expected to close in the fourth quarter of 2026.
Price Impact
More from SUPN